New List Out On Medicare Part B Drugs Eligible for Rebates
Some Medicare beneficiaries may pay lower coinsurance rates from April 1 to June 30 for the drugs, HHS says.
The Department of Health and Human Services (HHS) has released a new list of Medicare Part B drugs that will have lower coinsurance rates from April 1 to June 30 if drugmakers raise their prices faster than the rate of inflation.
Under the Medicare Prescription Drug Inflation Rebate Program, some beneficiaries that use one or more of the 41 rebatable drugs on the list may save between $1 and $3,575 per average dose depending on their coverage, the HHS said. The agency estimates that 763,700 people with Medicare use one or more of the 41 drugs annually.
Last December, the agency released its first-quarter 2024 list of rebatable drugs under the program. There were 48 drugs in that list and Medicare coinsurance for certain Part B drugs on the list were expected to save some beneficiaries up to $2,786 per dose, HHS said at the time.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Drug companies are required to pay the rebates for certain drugs to Medicare when prices increase faster than inflation as part of the Biden administration’s Inflation Reduction Act, which established the program.
HHS Secretary Xavier Becerra said in a statement that the administration “will continue to use every lever we have to lower healthcare costs for more Americans.”
Drug price talks continue
In addition, drugmakers participating in Medicare's price talks on the first 10 Part D drugs sent counteroffers to the agency earlier this month, following Medicare's initial offer in February.
The drugs, covered under Part D, are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog.
Negotiations are slated to end August 1. New negotiated prices for the drugs expected to be announced by September 1, with an effective date of January 2026.
Guidance on Medicare programs
The Centers for Medicare & Medicaid Services (CMS) provides a variety of guidance documents on the rebatable drugs, price negotiations with drugmakers, and other Medicare programs. For more information on reducing coinsurance for certain Part B rebatable drugs under the Medicare prescription drug inflation rebate program, see this CMS fact sheet.
HHS also has launched LowerDrugCosts.gov, a new website for Medicare beneficiaries with information related to the drug pricing provisions under the Inflation Reduction Act as well as resources for Medicare enrollees and other interested parties.
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
California Fires: How to Recover Your Tax Records and Other Important Documents
Disaster Recovery Having your tax records and other vital documents is important for claiming casualty loss deductions that can help with recovery.
By Gabriella Cruz-Martínez Published
-
10 Reasons to Leave Your Heirs a Roth IRA
Including a Roth IRA in your estate plan has clear tax advantages, which can be passed along to your heirs for years to come. But if passed down incorrectly, your heirs won’t reap the full benefits.
By Kathryn Pomroy Published
-
10 Reasons to Leave Your Heirs a Roth IRA
Including a Roth IRA in your estate plan has clear tax advantages, which can be passed along to your heirs for years to come. But if passed down incorrectly, your heirs won’t reap the full benefits.
By Kathryn Pomroy Published
-
The Cheapest Places To Retire in the US
When you're trying to balance a fixed income with an enjoyable retirement, cost of living is a crucial factor to consider.
By Stacy Rapacon Published
-
Social Security and Medicare Funding: Is the Sky Falling?
Social Security and Medicare are slowly running out of money, but what does that mean for the retirees counting on them? Actually, it's not all bad news.
By Jared Elson, Investment Adviser Published
-
What We Need to Do to Protect Retirees' Financial Security
Cognitive decline and aging in general put older retirees at risk of losing their financial security when they're the most vulnerable. What can be done?
By Margaret Franklin, CFA Published
-
Why You Should Check Your College's Financial Health
Colleges throughout the country are struggling financially as enrollment shrinks and expenses rise, making it important to check the financial health of the college your or your child is attending.
By Kimberly Lankford Published
-
Where to Store Your Cash in 2025
Take a fresh look at budgeting and savings opportunities for where to store your cash this year, to ensure you leave no stone unturned.
By Sean Jackson Published
-
Financial Planning: Sisters Should Be Doin' It for Themselves
More and more women are ringin' on their own financial bells (with apologies to Aretha Franklin and Eurythmics) — but that demands a robust financial plan.
By Laura Combs, CFP® Published
-
The Verizon Administrative Settlement Payment is a Reminder Class-Action Lawsuits Won't Make You Rich
People are receiving payouts from the Verizon administrative settlement and are surprised at how small they are. This provides a helpful financial lesson reminder.
By Alexandra Svokos Published